McLachlan A - Search Results

1

Efficacy, safety, and dose-dependence of the analgesic effects of opioid therapy for people with osteoarthritis: systematic review and meta-analysis.

Abdel Shaheed C, Awal W, Zhang G, Gilbert SE, Gallacher D, McLachlan A, Day RO, Ferreira GE, Jones CM, Ahedi H, Tamrakar M, Blyth FM, Stanaway F, Maher CG. Abdel Shaheed C, et al. Among authors: mclachlan a. Med J Aust. 2022 Apr 4;216(6):305-311. doi: 10.5694/mja2.51392. Epub 2022 Feb 9. Med J Aust. 2022. PMID: 35137418 Review.

2

Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate.

Tett SE, McLachlan AJ, Cutler DJ, Day RO. Tett SE, et al. Among authors: mclachlan aj. Chirality. 1994;6(4):355-9. doi: 10.1002/chir.530060420. Chirality. 1994. PMID: 8068493

3

Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemate.

McLachlan AJ, Tett SE, Cutler DJ, Day RO. McLachlan AJ, et al. Chirality. 1994;6(4):360-4. doi: 10.1002/chir.530060421. Chirality. 1994. PMID: 8068494

4

Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis.

McLachlan AJ, Tett SE, Cutler DJ, Day RO. McLachlan AJ, et al. Br J Rheumatol. 1994 Mar;33(3):235-9. doi: 10.1093/rheumatology/33.3.235. Br J Rheumatol. 1994. PMID: 8156285 Clinical Trial.

5

Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine.

Tett S, McLachlan A, Day R, Cutler D. Tett S, et al. Among authors: mclachlan a. Agents Actions Suppl. 1993;44:145-90. Agents Actions Suppl. 1993. PMID: 8372723

6

Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate.

McLachlan AJ, Tett SE, Cutler DJ, Day RO. McLachlan AJ, et al. Br J Clin Pharmacol. 1993 Jul;36(1):78-81. doi: 10.1111/j.1365-2125.1993.tb05897.x. Br J Clin Pharmacol. 1993. PMID: 8373715 Free PMC article. Clinical Trial.

7

Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects.

Graham S, Day RO, Wong H, McLachlan AJ, Bergendal L, Miners JO, Birkett DJ. Graham S, et al. Among authors: mclachlan aj. Br J Clin Pharmacol. 1996 Apr;41(4):299-304. doi: 10.1046/j.1365-2125.1996.03116.x. Br J Clin Pharmacol. 1996. PMID: 8730975 Free PMC article. Clinical Trial.

8

Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid.

Day RO, McLachlan AJ, Graham GG, Williams KM. Day RO, et al. Among authors: mclachlan aj. Clin Pharmacokinet. 1999 Mar;36(3):191-210. doi: 10.2165/00003088-199936030-00002. Clin Pharmacokinet. 1999. PMID: 10223168 Review.

9

Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.

Davies NM, McLachlan AJ, Day RO, Williams KM. Davies NM, et al. Among authors: mclachlan aj. Clin Pharmacokinet. 2000 Mar;38(3):225-42. doi: 10.2165/00003088-200038030-00003. Clin Pharmacokinet. 2000. PMID: 10749518 Review.

10

Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women.

Wren BG, Day RO, McLachlan AJ, Williams KM. Wren BG, et al. Among authors: mclachlan aj. Climacteric. 2003 Jun;6(2):104-11. Climacteric. 2003. PMID: 12841880

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

668 results

Search Page

Filters